Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 5/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12919495 | 0.84 | CSNK1D (0.46) | SCN10AALPLALPIALPGKDM4E | |
| SCHEMBL12894033 | 0.76 | CACNA1H (0.37) | CACNA1HSCN10AALPLALPIALPG | |
| SCHEMBL20096687 | 0.76 | CACNA1H (0.41) | CACNA1HARTRPA1 | |
| SCHEMBL20096569 | 0.76 | CACNA1H (0.41) | CACNA1HARTRPA1 | |
| SCHEMBL1258416 | 0.74 | ALPL (0.45) | SCN10AALPLALPIALPGKDM4E | |
| SCHEMBL1635569 | 0.74 | AR (0.40) | CACNA1HARTRPA1 | |
| SCHEMBL1260391 | 0.73 | KDM4E (0.47) | SCN10AALPLALPIALPGKDM4E | |
| SCHEMBL1258546 | 0.73 | AR (0.51) | CACNA1HSCN10AARALPLALPI | |
| SCHEMBL12712490 | 0.73 | AR (0.51) | CACNA1HSCN10AARALPLALPI | |
| SCHEMBL12712487 | 0.73 | AR (0.51) | CACNA1HSCN10AARALPLALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812406-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-12 | — | — | EP | disclosed |
| EP-1805147-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-8586616-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-19 | — | — | US | disclosed |
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2011-04-14 | — | — | US | disclosed |
| US-7879895-B2 | prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-20100324095-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-12-23 | — | — | US | disclosed |
| US-20100298383-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2010-11-25 | — | — | US | disclosed |
| EP-2246334-A1 | MEDICINAL COMPOSITION FOR INHIBITING AMYLOID- PROTEIN DEPOSITION | Sumitomo Chemical Company, Limited (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-7795446-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-20090258909-A1 | Novel Benzimidazole Derivatives Useful as Selective Androgen Receptor Modulators (SARMS) | NG RAYMOND | 2009-10-15 | — | — | US | disclosed |
| US-7566733-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-28 | — | — | US | disclosed |
| US-7566733-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-28 | — | — | US | disclosed |
| US-20080119522-A1 | 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer | NG RAYMOND | 2008-05-22 | — | — | US | disclosed |
| US-7348438-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-25 | — | — | US | disclosed |
| EP-1812406-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-01 | — | — | EP | disclosed |
| US-20060116412-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| US-20060111402-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-25 | — | — | US | disclosed |
| WO-2006039215-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, ESRRA | CACNA1H 4263/4885SCN10A 3024/4885AR 1/4885 |
| US-20090258909-A1 | Novel Benzimidazole Derivatives Useful as Selective Androgen Receptor Modulators (SARMS) | AR, NR5A1, ESRRA | CACNA1H 4263/4885SCN10A 3024/4885AR 1/4885 |
| US-20100298383-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, ESRRA | CACNA1H 4263/4885SCN10A 3024/4885AR 1/4885 |
| US-20100324095-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | APP, PSEN1, APBA1 | CACNA1H 1762/4885SCN10A 149/4885AR 3720/4885 |
| US-20060111402-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | AR, NR5A1, ESRRA | CACNA1H 4263/4885SCN10A 3024/4885AR 1/4885 |
| US-20080119522-A1 | 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer | AR, FSHR, BRDT | CACNA1H 4641/4885SCN10A 4677/4885AR 1/4885 |
| US-20060116412-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | AR, NR5A1, ESRRA | CACNA1H 4263/4885SCN10A 3024/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.